We have developed a new prodrug therapeutic platform for cell, protein, and small molecule combination therapies termed “drugamers”. This platform has been initially developed against pulmonary infections, where they have shown excellent activity in highly lethal disease models. The platform has been further broadened to include other infectious disease targets such as malaria, HIV and SARS-CoV-2, as well as for oncology drug therapy with kinase inhibitors and chemotherapeutic drugs. Recent advances across these applications will be covered.
This virtual event will be stream online via/WebEX.
Friday, October 22 at 1:00pm to 2:00pmVirtual Event